Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138410 | 0.83 | PSMB8 (0.31) | — | |
| SCHEMBL213096 | 0.82 | ALDH1A1 (0.35) | MGLL | |
| SCHEMBL1700762 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL1981540 | 0.79 | CYP1A2 (0.42) | — | |
| SCHEMBL43576 | 0.79 | PSMB8 (0.35) | PARLMGLL | |
| SCHEMBL2618714 | 0.79 | MGLL (0.34) | PARLMGLL | |
| SCHEMBL596794 | 0.78 | MAPT (0.44) | — | |
| SCHEMBL3489296 | 0.78 | TSHR (0.41) | — | |
| SCHEMBL26978299 | 0.78 | MAPT (0.44) | — | |
| SCHEMBL3805679 | 0.77 | MGLL (0.33) | PARLMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| US-10016512-B2 | Immobilised biological entities | CARMEDA AB (SE) | 2018-07-10 | — | — | US | disclosed |
| US-20180140713-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2018-05-24 | — | — | US | disclosed |
| US-20170368237-A1 | IMMOBILISED BIOLOGICAL ENTITIES | GORE & ASS (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
| US-9764068-B2 | Immobilised biological entities | W.L. GORE AND ASSOCIATES INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9645140-B2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160310646-A1 | IMMOBILISED BIOLOGICAL ENTITIES | W. L. GORE & ASSOCIATES, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160228572-A9 | Immobilised Biological Entities | CARMEDA AB (SE) | 2016-08-11 | — | — | US | disclosed |
| US-9408950-B2 | Immobilised biological entities | W.L. GORE & ASSOCIATES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-8501212-B2 | Immobilised biological entities | CARMEDA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120301894-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120231043-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2012-09-13 | — | — | US | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110223229-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110223229-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009102820-A2 | MODIFIED SUGAR SUBSTRATES AND METHODS OF USE | GOVERNMENT OF THE U.S A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223229-A1 | IMMOBILISED BIOLOGICAL ENTITIES | FGB, SELE, EPCAM | PARL 3718/4885MGLL 2325/4885 |
| US-20180140713-A1 | IMMOBILISED BIOLOGICAL ENTITIES | FGB, SELE, EPCAM | PARL 3718/4885MGLL 2325/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | PARL 4713/4885MGLL 1285/4885 |
| US-10016512-B2 | Immobilised biological entities | FGB, SELE, EPCAM | PARL 3718/4885MGLL 2325/4885 |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | PARL 2533/4885MGLL 3813/4885 |
| US-20120231043-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CD44, CD63, FGB | PARL 3624/4885MGLL 2615/4885 |
| US-20160228572-A9 | Immobilised Biological Entities | FGB, SELE, EPCAM | PARL 3718/4885MGLL 2325/4885 |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | PARL 2533/4885MGLL 3813/4885 |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | PARL 2659/4885MGLL 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.